Renal Cell Carcinoma: Evolution of First-Line Clinical Trials

In this segment, Dr. Elizabeth Plimack and Dr. Yasser Ged explore how clinical trials in renal cell carcinoma have evolved, particularly in the first-line setting. The discussion highlights the shift from earlier trials focused primarily on single-agent therapies and progression-free survival to more complex study designs evaluating combination regimens, including immune checkpoint inhibitors and targeted therapies. Dr. Ged outlines how modern trials in renal cell carcinoma increasingly incorporate multiple efficacy endpoints such as overall survival, objective response rate, and durability of response, reflecting a broader understanding of meaningful clinical benefit. The conversation also addresses rising expectations for treatment outcomes, with an emphasis on achieving deeper and more durable responses earlier in the disease course. This evolution in trial design has helped shape current treatment strategies and continues to inform how clinicians interpret evidence and apply it to real-world decision-making in renal cell carcinoma.